Ticker: CBPO, Company: China Biologic Products, Inc., Type: 8-K, Date: 2016-02-25
Original SEC Filing: Click here

---

Webplus: CBPO/20160225/8-K/2_EX-10.1/000.htm SEC Original: v432601_ex10-1.htm
CHINA BIOLOGIC PRODUCTS, INC. AMENDED AND RESTATED DIRECTOR AGREEMENT Agreement Company Mr. David Li Director THIS AGREEMENT (this “ BACKGROUND Original Agreement The Director and the Company entered into a director agreement (the “ The Director and the Company desire to enter into this Agreement to amend and restate the Original Agreement in its entirety. AGREEMENT In consideration for the

---

---

Webplus: CBPO/20160225/8-K/3_EX-99.1/000.htm SEC Original: v432601_ex99-1.htm
FOR RELEASE February 25, 2016 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2015 4Q15 Total Sales Up 22.6% with Non-GAAP Net Income Up 44.5% YoY in RMB terms, or Up 17.8% YoY to $68.3 Million and 38.8% YoY to $20.4 Million in USD terms, respectively FY15 Total Sales Up 23.4% with Non-GAAP Net Income Up

---

---

Webplus: CBPO/20160225/8-K/1/000.htm SEC Original: v432601_8k.htm

---

Company Information:

Ticker: CBPO, Company: China Biologic Products, Inc., Type: 8-K, Date: 2016-02-25CIK: 0001369868, Location: F4, SIC: 2836, SIC Desc: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Business Phone & Address:
18TH FL, JIALONG INTERNATIONALBUILDING
BEIJING 100125